# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately...
Maxim Group analyst Jason McCarthy initiates coverage on Lipella Pharmaceuticals (NASDAQ:LIPO) with a Buy rating and announc...
Lipella Pharmaceuticals Inc.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...